All Type of News
‘Toujeo,’ next-generation basal insulin, has been approved, competing against ‘Tresiba’
A number of next-generation long-acting basal insulin, which decreased risks in hypoglycemia occurrence, is about to enter the domestic market.
According to the industry concerned on the 14th, Sanofi-Aventis’s next-g...
The National Health Insurance partially won the lawsuit against GSK and Dong-A ST
It was ruled that the National Health Insurance budget wasted and reduced by price-fixing among pharmaceutical companies needs to be compensated by the pharmaceutical companies to the National Health Insurance Service...
The Korea Pharmaceutical Distribution Association declared firm fight against Hanmi Pharm
The Korea Pharmaceutical Distribution Association(KPDA) has started a firm fight, requesting suspension of Hanmi Pharm’s infringement to the pharmaceutical distribution right.
The KPDA(President Chi-yup Hwang) held a...
Dong-A ST has begun to develop a new improved drug avoiding the patent of VireadAs Dong-A ST has acquired approval to conduct a clinical study for a new improved drug of the blockbuster hepatitis B treatment, Viread(generic name: tenofovir) and started its ...
|
The monopolistic market shaken by approval of a domestic tetravalent flu vaccine
Green Cross, a domestic vaccine manufacturer, will enter the tetravalent influenza vaccine market, which was expected to be led by GSK during this season(2015-2016).
Green Cross has started to conduct a Phase 3 clini...
Will a blockbuster-level treatment emerge in the hepatitis C treatment market?
Followed by the hepatitis B treatment market, having excellent marketability even allowing a single-substance product to record KRW 150 billion prescriptions, the hepatitis C treatment market has also been accelerated...
Did Atozet impact on sales decrease of Vytorin, resulting winning of Lipitor in the first half?
Although MSD Korea has pressured Pfizer Korea’s ‘Lipitor(generic name: atorvastatin)’ by launching ‘Atozet,’ a hyperlipidemia treatment adding ‘atorvastatin’ in ‘ezetimibe,’ this April, it was not able to make a succe...
The Korea Pharmaceutical Distribution Association resumes attacks toward Pfizer and Novartis
The Korea Pharmaceutical Distribution Association(KPDA) will resume attacks towards Pfizer and Novartis providing distribution margins not even meeting the break-even point.
The KPDA is scheduled to held an expanded ...
The last year’s health insurance benefit was KRW 13.4 trillion, increasing 3.2 times up in 14 years
It is observed that medicine cost of the national health insurance increased 3.2 times higher than the one 14 years ago.
According to the ‘Combined Reports of the 2014 Health Insurance Propriety Assessment Result,’ u...
Huge increase of foreign CROs threaten domestic companies in the domestic clinical study market
In the recent domestic clinical study market, market share of foreign CRO companies have made significant increases, threatening domestic CROs.
In particular, CRAs, key human resources in the market, prefer foreign c...
